NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Old Version 3

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

compared with

New Version Current

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Amy LeblancX

Otridge, John (NIH/NCI) [C]


X
Kim, Erika (NIH/NCI) [E]

X

Sommers, Connie (NIH/NCI) [E]

X


Debbie Knapp
X
Toby HechtX
Ralph ParchmentX

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

...

ItemWhoTalking Points
Discussion of potential submission of FidoCure  Animal Health data

Sommers, Connie (NIH/NCI) [E] 

  • Create wish list of data to request from FidoCure
New article from Purdue Office of ResearchDebbie Knapp
DGAB Updates

Kuffel, Gina (NIH/NCI) [C] 

New Data Submission Request

  • Link to data submission request form
  • Osteosarcoma study from Auburn University
  • 7 cases
  • Clinical and Transcriptomic data
  • Presented to DGAB on 7/24/23

Recently Approved

  • COTC021
    • "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
    • 152 186 cases, 93 186 files
    • Full clinical dataset is available for both arms of this trial (324 dogs)
    • Scan H & E is available
    • Status: Approved by SAC on 6/30/23, templated-based loading files have been received, waiting on files and file transfer manifest

ICDC Studies in Active Submission

  • ORGANOIDS01
    • Approved by SAC on 9/22/22
    • “Characterization of healthy and diseased canine tissues and organoids"
    • Iowa State University
    • Status: Data has been loaded to the Dev and QA tiers, all files have been indexed by DCF team, testing is in progress
BPSC Updates

Kuffel, Gina (NIH/NCI) [C] 

  • 2022 BPSC Review Article

    The manuscript entitled "Leading the Pack: Best Practices in Comparative Canine Cancer Genomics to Inform Human Oncology" has been accepted by the journal of Veterinary and Comparative Oncology. The ICDC will pay to ensure this article is open access.

Upcoming Steering Committee Meeting

Unknown User (parchmentr)Ralph Parchment

  • Enter date: Wednesday September 20th
2023 Q2 Software Release

Kuffel, Gina (NIH/NCI) [C] 

  • Released on August 15, 2023
  • New Features
    • JBrowse now supports text search so go ahead and find your favorite gene (Try it…Visit this page, select GLIOMA01 under the “Study” facet, and then click on the “Case Files” tab, select the first BAM file and click the “View in JBrowse” button, enter TP53 into the text search bar)
    • JBrowse has a new track that maps gene features from hg38 to canFam3
    • The Study, Study Details, and Program Details pages now feature interoperability between the ICDC, the Imaging Data Commons, and the Cancer Imaging Archive through the use of APIs to fetch details about imaging data hosted outside of the ICDC
    • Clinical observation data is now available for download on a node-by-node basis through a dedicated tab within the Study Details page
    • The Privacy Policy is now available within the footer of the Landing page
    • Updates to the ICDC News page
    • New README available within the “My Files” Cart page

Minutes (Not Verbatim)

AL - Jerry Post agreed that it is an exciting time for canine oncology. He thinks it would be a good idea for us to connect more. He expressed some concerns with integrating their data with our committee. They have novel data that would be interesting for the ICDC. Vidium has a publication out and may be more willing to share data.

TH - We should schedule a formal session with both groups to reconnect.

TH - Debbie has been in touch and has a paper that has been accepted that actually uses ICDC data.

TH - Cancer health disparity in acral melanoma in African Americans. Human dog comparative oncology could be important.

AL - Will H. has a paper that performs a broad assessment of canine melanomas in dogs

Lets get the data they have (my understanding is they conduct hotspot panels primarily from FFPE samples), lets get the genomic files, the demographic data and the histological or cytological data. If they have treatment and outcome data that would be valuable. This data would only be useful if we have these dimensions. Some data may come from dogs that were immediately euthanized or treated through palliative care.

TH - We may want to focus on specific malignancies and perhaps cases to augment osteosarcoma and bladder cancer. We could tell them the cancer types we are specifically interested in. 

AL - A good example would be mast cell tumors, there would be value in them even though they are most prevalent in canine, but could serve researchers interested in KIT. Maybe they could send us a rough manifest of the type of histological canine cases they have to serve as a starting point.

TH - Or we can give them a list of histologies that we are interested in along with anything that has commonalities with human. We have to figure out what is the best thing for us to do since there will be an associated cost.

AL - We need to find out what specifically is on the hotspot panelJO - Did we want to find out if there is publicly available data on this and bring it into the ICDC?


Previous ICDC Use Cases from Steering Committee

...

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Action items

  •  Kuffel, Gina (NIH/NCI) [C] to relay info to Debbie for cancer types of interest to request from FidoCure: Glioma, osteosarcoma, bladder cancer, mucosal and acral melanoma, mast cell tumor. Request overview of what they have in their DB.